Overview and Scope
Hypolipidemic drugs refer to any substance that lowers the blood’s concentration of lipids and lipoproteins (lipid-protein complexes). Lipoproteins can build up in blood arteries and bind cholesterol. Its alternate name is lipid-lowering medication.
Sizing and Forecast
The hypolipidemics market size has grown steadily in recent years. It will grow from $28.65 billion in 2023 to $29.93 billion in 2024 at a compound annual growth rate (CAGR) of 4.5%. The growth in the historic period can be attributed to increasing prevalence of hyperlipidemia, lifestyle changes, aging population, awareness and screening, statin dominance.
The hypolipidemics market size is expected to see steady growth in the next few years. It will grow to $34.93 billion in 2028 at a compound annual growth rate (CAGR) of 3.9%. The growth in the forecast period can be attributed to personalized medicine, expanding patient pool, emerging markets, government initiatives, combination therapies. Major trends in the forecast period include shift from ldl to non-hdl cholesterol management, digital health and telemedicine, market consolidation and competition, patient-centric approaches.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/hypolipidemics-global-market-report
Segmentation & Regional Insights
The hypolipidemics market covered in this report is segmented –
1) By Product Type: Cholic Acid Regulator, HMG-CoA Reductase Inhibitors, Adenylate Cyclase Inhibitors, Nicotinic Acid Drugs, Other Types
2) By Drug Type: Statins, Bile Acid Sequestrants, Cholesterol Absorption Inhibitors, PCSK9 Inhibitors, Other Drug Types
3) By Application: Hospital, Clinics, Pharmacy, Cardiovasology
North America was the largest region in the hypolipidemic drugs market in 2023. The Middle East is expected to be the fastest-growing region in the hypolipidemic drugs market during the forecast period. The regions covered in the hypolipidemics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2435&type=smp
Major Driver Impacting Market Growth
Shifts in diet and changes in lifestyles of people are driving the growth of the hypolipidemic drugs market. An increase in the consumption of unhealthy food, and the rising prevalence of smoking and drinking have led to an increase in the level of cholesterol intake in people. For instance, in June 2021, according to the World Health Organization data 2021, a Switzerland-based Government agency responsible for international public health, cardiovascular diseases (CVDs) are the leading cause of death globally, taking an estimated 17.9 million lives each year. The rising levels of cholesterol due to changes in lifestyles of the people is rising demand for hypolipidemic drugs as they aid in lowering the cholesterol levels.
Key Industry Players
Major companies operating in the hypolipidemics market include Abbott Laboratories Limited, Apotex Fermentation Inc., Biocon Limited, Cadila Healthcare Limited, Chunghwa Chem Syn& Biotech Co. Ltd., Concord Biotech Limited, Croda Europe Limited, Daiichi Sankyo Company Limited, Dr. Reddy’s Laboratories Ltd., DSM Sinochem Pharma India Pvt. Ltd., Hikal Chemicals Industries Limited, Ipca Laboratories Ltd., Lek Pharmaceuticals D.d, Lupin Limited, Merck Sharp & Dohme B.V, Mylan N.V, Nexchem Pharmaceutical Co. Ltd., Olon S.p.A, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Zhejiang Jiangbei Pharma Co. Ltd., Moehs Iberica S.L. ES, Pfizer Inc., Recordati S.p.A., AstraZeneca Plc, Amgen Plc, Daiichi Sankyo Company Limited, Kowa Company Ltd., Sanofi-Aventis, Novartis AG, Viatris Inc., Pfizer Inc., GlaxoSmithKline plc, Cipla Limited, Torrent Pharmaceuticals Ltd., Zydus Lifesciences Limited, Wockhardt Limited, Alembic Pharmaceuticals Limited, Jubilant Life Sciences Limited, Hetero Drugs Limited, Ind-Swift Laboratories Ltd., Intas Pharmaceuticals Ltd., Unichem Laboratories Ltd.
The hypolipidemics market report table of contents includes:
1. Executive Summary
2. Market Characteristics
3. Market Trends And Strategies
4. Impact Of COVID-19
5. Market Size And Growth
6. Segmentation
7. Regional And Country Analysis
.
.
.
27. Competitive Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
Related Reports:
https://goodprnews.com/fiber-lasers-market-size/
https://goodprnews.com/fungicides-market-share-insights/
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Electronic Materials Market Overview The global Electronic Materials Market was valued at USD 62.7 billion in 2023 and is…
The yeast infection treatment market size is expected to see strong growth in the next…
The 3d and 4d technology global market report 2024 from The Business Research Company provides…
Quantum Computing Market Size: The global Quantum Computing Market was valued at USD 2.96 billion in 2023…
Fluorspar Market Overview Fluorspar, a mineral composed mainly of calcium fluoride, plays a pivotal role…
Cold Chain Monitoring Market Overview: The Cold Chain Monitoring Market is experiencing robust growth, with an estimated…